Digital Marketing Trends for 2024
July 24, 2024
Ampersand wins £22m five-year contract at London Zoo
June 25, 2012
Why Americans lost interest in Olympics
July 25, 2024
The FINANCIAL -- Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 ...
The FINANCIAL -- AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union ...
The FINANCIAL -- AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability ...
The FINANCIAL -- AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure ...
The FINANCIAL -- AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil ...
The FINANCIAL -- AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) ...
The FINANCIAL -- AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been recommended for marketing authorisation in the European Union (EU) for maintenance ...
The FINANCIAL -- The outcome of vaccine trials is being closely watched around the world. Pharmaceutical company AstaZeneca said Tuesday that ...
news (at) financial.ge Letters to the Editor: editor (at) finchannel.com
Local Marketing contact:
(+99532) 2252 275 | 76 EXT: 1 (+995 558) 03 03 03 (mobile) marketing (at) finchannel.com
Requests from abroad:
(+99532) 2252 275 | 76 EXT: 7 (+995599) 96 52 52 Email: zviadi (@) finchannel.com Contact video editor: E-mail: video (at) financial.ge
Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL